Screener
Monopar Therapeutics MNPR Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | March 31, 2026 | December 31, 2025* |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,699,062 and 6,692,140 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively | 6,699 | 6,692 |
| Additional paid-in capital | 228,691,772 | 227,199,002 |
| Accumulated other comprehensive income (loss) | 98,521 | 131,389 |
| Retained earnings (accumulated deficit) | (93,402,580) | (89,509,530) |
| Total stockholders’ equity | 135,394,412 | 137,827,553 |
| Total liabilities and stockholders’ equity | $137,983,725 | $140,717,709 |
Document
FAQ
- What is Monopar Therapeutics's retained earnings?
- Monopar Therapeutics (MNPR) reported retained earnings of -$93.4M in Q1 2026.
- How has Monopar Therapeutics's retained earnings changed year-over-year?
- Monopar Therapeutics's retained earnings decreased by 19.1% year-over-year, from -$78.42M to -$93.4M.
- What is the long-term trend for Monopar Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Monopar Therapeutics's retained earnings has grown at a 22.7% compound annual growth rate (CAGR), from -$32.19M to -$89.51M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Monopar Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude